OM1, Inc.

OM1, Inc. is a healthcare technology company based in the US that utilizes artificial intelligence and real-world data to enhance research and support personalized medicine solutions for various health conditions. Founded in 2015 and headquartered in Boston, US, OM1, Inc. focuses on utilizing advanced analytics to enhance healthcare research.

The company has engaged in five funding rounds, with the latest being a Series D round in July 2021, raising USD 85. 00 mn. Rich Gliklich serves as the CEO and is also the founder of the company. OM1 specializes in leveraging artificial intelligence (AI) and real-world data (RWD) to enhance research and develop personalized medicine solutions.

The company’s core product offerings include advanced analytics platforms that extract and analyze data from clinical notes to identify psychiatric comorbidities and medication side effects. Additionally, OM1 provides tools for digital phenotyping, which utilizes data from a network encompassing over 300 million lives to generate personalized insights regarding treatment effectiveness, diagnosis, and risk assessment. These products are primarily utilized in the life sciences sector, focusing on areas such as immunology, mental health, cardiometabolic conditions, and rheumatology. OM1 serves a diverse client base that includes pharmaceutical companies, research institutions, and healthcare providers in North America and Europe.

OM1 generates revenue through a combination of subscription-based models and partnerships with healthcare organizations and life sciences companies. Clients engage with OM1's platforms for access to real-time analytics and insights derived from extensive health data repositories. The pricing structure typically involves tiered subscription plans that grant varying levels of access to analytical tools and data granularity based on the specific needs of the client. These transactions facilitate a robust framework for collaboration, allowing clients to utilize OM1's advanced analytics in their research, clinical trials, and decision-making processes.

Flagship services such as PhenOM® and custom data cohorts are integral to the company's revenue model, providing tailored solutions that address specific client requirements in the evolving landscape of healthcare analytics. In July 2021, OM1, Inc. raised USD 85. 00 mn in Series D funding co-led by new investors Breyer Capital, D1 Capital Partners, and Kaiser Permanente Ventures, with participation from returning investors 7-Wire Ventures, General Catalyst Partners, Glikvest, Polaris Partners, and Scale Venture Partners.

The funding will be utilized to expand OM1's product offerings. The company plans to introduce new analytics tools designed to improve treatment personalization by mid-2022 and targets expansion into European markets by the end of 2023.